- Home
- ARAI vs IFRX Comparison
ARAI vs IFRX Comparison
Compare ARAI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARAI | IFRX |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.6M | 60.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ARAI | IFRX |
|---|---|---|
| Price | $1.19 | $0.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $12.00 | $8.50 |
| AVG Volume (30 Days) | ★ 2.5M | 500.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $900.00 | $1,054.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $0.71 |
| 52 Week High | $40.00 | $2.02 |
Technical Indicators
Market Signals| Indicator | ARAI | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 27.10 | 40.73 |
| Support Level | $1.06 | $0.81 |
| Resistance Level | $1.56 | $0.90 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 10.31 | 21.01 |
Price Performance
Historical ComparisonAbout ARAI Arrive AI Inc.
Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advanced chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.